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QUESTIONS
1. What is dimethylfumarate?
2. How does angiogenesis play a role in the pathogenesis of psoriasis?
3. What were the results of the study?
4. What were the conclusions?
A middle-aged gentleman who recently moved from Germany presents 
at your office for the first time. He has a long history of psoriasis and 
has been treated with multiple modalities, including UV radiation and 
the medication dimethylfumarate (DMF). You note that, despite his his-
tory of severe psoriasis, his skin does not show many psoriatic plaques. 
Additionally, despite his use of phototherapy and natural sunlight to 
help control his psoriasis, you notice that he does not have any cancer-
ous or precancerous skin lesions.
This patient’s visit prompts the following questions. What is DMF? 
How effective is it in treating psoriasis? Is it a coincidence that this 
patient does not have evidence of skin neoplasias? You learn that DMF 
is a commonly used oral agent for the treatment of psoriasis in Europe 
(Brewer and Rogers, 2007). In fact, this compound has been used for 
more than 50 years, is the most commonly used oral agent for the treatment of psoriasis in Germany, and has good 
efficacy and safety profiles. Thought to inhibit proinflammatory cytokines, DMF also inhibits the transcription fac-
tor NF-κB, thus blocking downstream targets involved in the development and progression of inflammatory cas-
cades; however, its role in the development of neoplasia is still uncertain.
Various disease processes, including tumors, diabetic retinopathy, arthritis, and psoriasis, involve angio-
genesis (Fried and Arbiser, 2008). García-Caballero and colleagues (2011, this issue) examined the ability of DMF 
to influence neoplasia—specifically, the angiogenesis that is associated with it. Using in vivo and in vitro models, 
these researchers tested the hypothesis that DMF inhibits angiogenesis. The studies revealed that DMF inhib-
ited growth of transformed and nontransformed cells in a dose-dependent manner, in part because of the induc-
tion of apoptosis. In addition, inhibition of angiogenesis was observed in vivo. This inhibition may contribute 
to the effects of DMF on psoriasis and offer potential for this drug as a treatment for tumors. Through the fol-
lowing questions, we examine this paper in greater detail. For brief answers, please refer to the supplementary 
information online <http://www.nature.com/jid/journal/v131/n6/suppinfo/jid2011105s1.html>.
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